Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)
3 other identifiers
expanded_access
N/A
0 countries
N/A
Brief Summary
This is a treatment use study to provide early access to MK0518 for the treatment of HIV-1 infection in patients who have limited or no treatment options due to virological failure, resistance, or intolerance to multiple antiretroviral regimens. Enrollment in this study is patient driven. Investigators are not proactively assigned. There is no target sample size and duration of the study is indefinite. For information on how to enroll in the study, see link below.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 14, 2006
CompletedFirst Posted
Study publicly available on registry
September 15, 2006
CompletedApril 22, 2016
April 1, 2016
September 14, 2006
April 21, 2016
Conditions
Interventions
raltegravir 400 mg P.O. bid tablet twice daily for 12 weeks
Eligibility Criteria
You may qualify if:
- HIV positive patients who have limited or no treatment options and have documented resistance
You may not qualify if:
- Patient has previously been on MK0518 therapy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Medical Monitor
Merck Sharp & Dohme LLC
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 14, 2006
First Posted
September 15, 2006
Last Updated
April 22, 2016
Record last verified: 2016-04